Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.709
-$0.0449-5.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.89M | 7.80M | 8.19M | 8.72M | 8.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.80M | 34.13M | 37.24M | 40.44M | 39.50M |
| Operating Income | -30.80M | -34.13M | -37.24M | -40.44M | -39.50M |
| Income Before Tax | -29.90M | -33.00M | -35.97M | -39.82M | -39.24M |
| Income Tax Expenses | 19.50K | 10.20K | 22.30K | 21.30K | 16.90K |
| Earnings from Continuing Operations | -29.92 | -33.01 | -35.99 | -39.84 | -39.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.92M | -33.01M | -35.99M | -39.84M | -39.26M |
| EBIT | -30.80M | -34.13M | -37.24M | -40.44M | -39.50M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.92 | -1.10 | -1.33 | -1.59 | -1.66 |
| Normalized Basic EPS | -0.57 | -0.69 | -0.83 | -1.00 | -1.04 |
| EPS Diluted | -0.92 | -1.10 | -1.33 | -1.59 | -1.66 |
| Normalized Diluted EPS | -0.57 | -0.69 | -0.83 | -1.00 | -1.04 |
| Average Basic Shares Outstanding | 132.56M | 121.47M | 111.31M | 103.19M | 95.13M |
| Average Diluted Shares Outstanding | 132.56M | 121.47M | 111.31M | 103.19M | 95.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |